UroGen Pharma (URGN) Set to Announce Quarterly Earnings on Wednesday

UroGen Pharma (NASDAQ:URGN) is scheduled to be announcing its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to analyst estimates of $23.69 million. On average, analysts expect UroGen Pharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

UroGen Pharma Stock Down 0.9 %

Shares of NASDAQ URGN traded down $0.11 on Tuesday, reaching $11.82. 204,812 shares of the company’s stock traded hands, compared to its average volume of 501,501. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23. The business’s 50 day simple moving average is $12.90 and its two-hundred day simple moving average is $14.22. UroGen Pharma has a 12 month low of $10.60 and a 12 month high of $20.70. The company has a market cap of $277.23 million, a price-to-earnings ratio of -3.67 and a beta of 1.12.

Analyst Ratings Changes

A number of research firms have recently commented on URGN. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Oppenheimer restated an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. Guggenheim began coverage on shares of UroGen Pharma in a research note on Thursday, August 22nd. They issued a “buy” rating and a $40.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $48.38.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.